Literature DB >> 22547420

Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.

Emily M Van Meter1, Elizabeth Garrett-Mayer, Dipankar Bandyopadhyay.   

Abstract

BACKGROUND: Various dose-finding clinical trial designs, including the continual reassessment method (CRM), dichotomize toxicity outcomes based on prespecified dose-limiting toxicity (DLT) criteria. This loss of toxicity information is particularly inefficient due to the small sample sizes in phase I trials, especially when Common Terminology Criteria for Adverse Events (CTCAE v4.0) are an established ordinal toxicity grading classification already used in the clinical practice.
PURPOSE: The purpose of this simulation study is to incorporate ordinal toxicity grades as specified by CTCAE v4.0 using a continuation ratio (CR) model in the likelihood-based CRM.
METHODS: This simulation study compares the CR model design to the dichotomous CRM as well as an ordinal CRM that implements the proportional odds (PO) model. We compare six scenarios for model performance based on various safety and efficiency criteria and consider a range of dose-toxicity relationship models, including CR models, PO models, and models that violate the PO assumption.
RESULTS: The ordinal CRM performs as well as the dichotomous CRM in all scenarios considered, especially in situations where the starting dose is overly toxic, the ordinal designs show slight improvement in the estimation of the maximum tolerated dose (MTD) and fewer median patients exposed to excessively toxic dose levels as compared to the binary CRM. We also find slight discrepancies in the performance between the PO model and CR model; however, the differences were not substantial enough to strongly recommend one model over the other. LIMITATIONS: The CR model design does require slightly more input from clinical investigators prior to the start of the trial as compared to the dichotomous CRM. Investigators must specify the distribution of toxicity grades at the expected dose levels for a 10% and 90% DLT rate in this CR design. However, an R package will help with the implementation of this ordinal design.
CONCLUSIONS: While the ordinal designs did not perform significantly better than the binary counterpart, we were able to incorporate maximal toxicity information available into a feasible dose-finding design without compromising overall design performance.

Entities:  

Mesh:

Year:  2012        PMID: 22547420      PMCID: PMC5531273          DOI: 10.1177/1740774512443593

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  14 in total

Review 1.  Competing designs for phase I clinical trials: a review.

Authors:  William F Rosenberger; Linda M Haines
Journal:  Stat Med       Date:  2002-09-30       Impact factor: 2.373

2.  Incorporating lower grade toxicity information into dose finding designs.

Authors:  Alexia Iasonos; Sarah Zohar; John O'Quigley
Journal:  Clin Trials       Date:  2011-08       Impact factor: 2.486

Review 3.  Effectiveness of adaptive designs for phase II cancer trials.

Authors:  Martha Fors López; Jean-François Dupuy; Carmen Viada Gonzalez
Journal:  Contemp Clin Trials       Date:  2011-10-07       Impact factor: 2.226

4.  An evaluation of phase I cancer clinical trial designs.

Authors:  C Ahn
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

5.  Practical implementation of a modified continual reassessment method for dose-finding trials.

Authors:  S Piantadosi; J D Fisher; S Grossman
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

6.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

7.  Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.

Authors:  Emily M Van Meter; Elizabeth Garrett-Mayer; Dipankar Bandyopadhyay
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

8.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

9.  Alternative models for ordinal logistic regression.

Authors:  S Greenland
Journal:  Stat Med       Date:  1994-08-30       Impact factor: 2.373

10.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

View more
  16 in total

1.  A robust Bayesian dose-finding design for phase I/II clinical trials.

Authors:  Suyu Liu; Valen E Johnson
Journal:  Biostatistics       Date:  2015-10-20       Impact factor: 5.899

Review 2.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

3.  A decision-theoretic phase I-II design for ordinal outcomes in two cycles.

Authors:  Juhee Lee; Peter F Thall; Yuan Ji; Peter Müller
Journal:  Biostatistics       Date:  2015-11-09       Impact factor: 5.899

4.  Design considerations for dose-expansion cohorts in phase I trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

5.  Dose-finding designs for cumulative toxicities using multiple constraints.

Authors:  Shing M Lee; Moreno Ursino; Ying Kuen Cheung; Sarah Zohar
Journal:  Biostatistics       Date:  2019-01-01       Impact factor: 5.899

6.  An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials.

Authors:  Cody Chiuzan; Elizabeth Garrett-Mayer; Michael Nishimura
Journal:  Stat Biopharm Res       Date:  2018-04-30       Impact factor: 1.452

7.  Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy.

Authors:  Yun Chen; Zhen Zhang; Guoliang Jiang; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].

Authors:  Jing You; Huiming Yu; Maxiaowei Song; Chen Shi; Xiaohang Wang; Ye Zheng; Rong Yu; Anhui Shi; Guangying Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-01-20

9.  The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.

Authors:  Haitao Pan; Cailin Zhu; Feng Zhang; Ying Yuan; Shemin Zhang; Wenhong Zhang; Chanjuan Li; Ling Wang; Jielai Xia
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

10.  A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.

Authors:  Yun Chen; Zhengfei Zhu; Weixin Zhao; Ling Li; Jinjun Ye; Chaoyang Wu; Huarong Tang; Qin Lin; Jiancheng Li; Yi Xia; Yunhai Li; Jialiang Zhou; Kuaile Zhao
Journal:  Radiat Oncol       Date:  2018-02-27       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.